Published in Med Care on April 01, 2010
Lying to insurance companies: the desire to deceive among physicians and the public. Am J Bioeth (2004) 8.49
Use of prescription and over-the-counter medications and dietary supplements among older adults in the United States. JAMA (2008) 5.27
The effect of the Medicare Part D prescription benefit on drug utilization and expenditures. Ann Intern Med (2008) 4.33
Reconsidering medication appropriateness for patients late in life. Arch Intern Med (2006) 3.81
Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolesc Health (2009) 3.13
National trends in oral anticoagulant use in the United States, 2007 to 2011. Circ Cardiovasc Qual Outcomes (2012) 2.27
The Food and Drug Administration Amendments Act and postmarketing commitments. JAMA (2013) 2.27
Impact of FDA black box advisory on antipsychotic medication use. Arch Intern Med (2010) 2.05
National trends in cyclooxygenase-2 inhibitor use since market release: nonselective diffusion of a selectively cost-effective innovation. Arch Intern Med (2005) 2.01
Are Food and Drug Administration prescription drug safety plans working? A case study of isotretinoin. Pharmacoepidemiol Drug Saf (2013) 1.97
The role of surgeon error in withdrawal of postoperative life support. Ann Surg (2012) 1.97
The physician-surrogate relationship. Arch Intern Med (2007) 1.93
Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review. Med Care (2012) 1.91
Substituted judgment: the limitations of autonomy in surrogate decision making. J Gen Intern Med (2008) 1.88
The prescription opioid and heroin crisis: a public health approach to an epidemic of addiction. Annu Rev Public Health (2015) 1.86
General internists' views on pay-for-performance and public reporting of quality scores: a national survey. Health Aff (Millwood) (2007) 1.71
Outpatient hypertension treatment, treatment intensification, and control in Western Europe and the United States. Arch Intern Med (2007) 1.69
Promotion of prescription drugs to consumers and providers, 2001-2010. PLoS One (2013) 1.66
Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components. Am J Hypertens (2008) 1.60
Prioritizing future research on off-label prescribing: results of a quantitative evaluation. Pharmacotherapy (2008) 1.58
Critical care physicians' approaches to negotiating with surrogate decision makers: a qualitative study. Crit Care Med (2012) 1.54
Surgeons expect patients to buy-in to postoperative life support preoperatively: results of a national survey. Crit Care Med (2013) 1.53
Surgeon-reported conflict with intensivists about postoperative goals of care. JAMA Surg (2013) 1.49
Changes in glitazone use among office-based physicians in the U.S., 2003-2009. Diabetes Care (2010) 1.46
Responding to an FDA warning--geographic variation in the use of rosiglitazone. N Engl J Med (2010) 1.46
Impact of a drug utilization review program on high-risk use of prescription controlled substances. Pharmacoepidemiol Drug Saf (2013) 1.42
Impact of abuse-deterrent OxyContin on prescription opioid utilization. Pharmacoepidemiol Drug Saf (2014) 1.42
Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010. Med Care (2013) 1.40
Should editorials in peer-reviewed journals be signed? Chest (2006) 1.40
Recommendations to limit life support: a national survey of critical care physicians. Am J Respir Crit Care Med (2012) 1.39
Prescriptions, nonmedical use, and emergency department visits involving prescription stimulants. J Clin Psychiatry (2016) 1.39
National trends in ambulatory asthma treatment, 1997-2009. J Gen Intern Med (2011) 1.37
U.S. physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey. Pharmacoepidemiol Drug Saf (2009) 1.34
Ambulatory treatment of type 2 diabetes in the U.S., 1997-2012. Diabetes Care (2013) 1.32
Elderly patients' preferences and experiences with providers in managing their drug costs. J Am Geriatr Soc (2007) 1.21
Impact of Medicare Part D on Medicare-Medicaid dual-eligible beneficiaries' prescription utilization and expenditures. Health Serv Res (2009) 1.19
Racial and ethnic disparities in cardiovascular medication use among older adults in the United States. Pharmacoepidemiol Drug Saf (2010) 1.19
Physicians' experience with surrogate decision making for hospitalized adults. J Gen Intern Med (2009) 1.15
Trends in attention deficit hyperactivity disorder ambulatory diagnosis and medical treatment in the United States, 2000-2010. Acad Pediatr (2012) 1.15
Physician consideration of patients' out-of-pocket costs in making common clinical decisions. Arch Intern Med (2007) 1.11
The impact of the Medicare Part D prescription benefit on generic drug use. J Gen Intern Med (2008) 1.08
Rethinking the ethical framework for surrogate decision making: a qualitative study of physicians. J Clin Ethics (2008) 1.03
The impact of Medicare Part D on out-of-pocket costs for prescription drugs, medication utilization, health resource utilization, and preference-based health utility. Health Serv Res (2011) 0.98
National prevalence of lifestyle counseling or referral among African-Americans and whites with diabetes. J Gen Intern Med (2008) 0.94
Assessing competence of residents to discuss end-of-life issues. J Palliat Med (2005) 0.93
Mind the gap: understanding the effects of pharmaceutical direct-to-consumer advertising. Med Care (2014) 0.93
A qualitative exploration of depression in emerging adulthood: disorder, development, and social context. Gen Hosp Psychiatry (2007) 0.92
Physicians' views on the importance of patient preferences in surrogate decision-making. J Am Geriatr Soc (2010) 0.92
Trends in co-prescribing of antidepressants and tamoxifen among women with breast cancer, 2004-2010. Breast Cancer Res Treat (2012) 0.92
Should our well-child care system be redesigned? A national survey of pediatricians. Pediatrics (2006) 0.92
Adherence and HIV RNA Suppression in the Current Era of Highly Active Antiretroviral Therapy. J Acquir Immune Defic Syndr (2015) 0.91
Changes in antipsychotic use among patients with severe mental illness after a Food and Drug Administration advisory. Pharmacoepidemiol Drug Saf (2012) 0.89
Health plan utilization and costs of specialty drugs within 4 chronic conditions. J Manag Care Pharm (2013) 0.89
State Medicaid programs did not make use of prior authorization to promote safer prescribing after rosiglitazone warning. Health Aff (Millwood) (2012) 0.88
Effects of FDA advisories on the pharmacologic treatment of ADHD, 2004-2008. Psychiatr Serv (2013) 0.86
Design and evaluation of a workplace intervention to promote organ donation. Prog Transplant (2006) 0.86
Influence of patient race on physician prescribing decisions: a randomized on-line experiment. J Gen Intern Med (2009) 0.85
The "Hassle Factor": what motivates physicians to manipulate reimbursement rules? Arch Intern Med (2002) 0.84
Improving the Food and Drug Administration's mandate to ensure postmarketing drug safety. JAMA (2011) 0.84
The association between family structure, reports of illness and health care demand for children: evidence from rural Bangladesh. J Biosoc Sci (2009) 0.84
Trends in the use of buprenorphine by office-based physicians in the United States, 2003-2013. Am J Addict (2015) 0.83
A qualitative study of physicians' engagement in reducing healthcare disparities. J Natl Med Assoc (2007) 0.83
Trends in use of second-generation antipsychotics for treatment of bipolar disorder in the United States, 1998-2009. Psychiatr Serv (2012) 0.83
Turning and churning: loss of health insurance among adults in Medicaid. J Gen Intern Med (2009) 0.83
Primary Care Physicians' Knowledge And Attitudes Regarding Prescription Opioid Abuse and Diversion. Clin J Pain (2016) 0.82
Unsupported off-label use of cancer therapies: new challenges in the era of biopharmaceuticals. Expert Rev Pharmacoecon Outcomes Res (2011) 0.82
Effect of physician payment disclosure laws on prescribing. Arch Intern Med (2012) 0.80
Is treatment heterogeneity an Achilles' heel for comparative effectiveness research? Pharmacotherapy (2012) 0.79
Unsupported off-label chemotherapy in metastatic colon cancer. BMC Health Serv Res (2012) 0.79
Importance of distinguishing supported and unsupported off-label drug use. Arch Intern Med (2010) 0.79
Construct validity and factor structure of survey-based assessment of cost-related medication burden. Med Care (2015) 0.79
Primary care physicians' views of Medicare Part D. Am J Manag Care (2008) 0.78
Association between unemployment rates and prescription drug utilization in the United States, 2007-2010. BMC Health Serv Res (2012) 0.78
New technologies meeting old professional boundaries: the emergence of carotid artery stenting. J Am Coll Surg (2005) 0.78
Health information technology and physicians' knowledge of drug costs. Am J Manag Care (2010) 0.78
A practical physicians' guide to the Medicare drug benefit plan. Mayo Clin Proc (2006) 0.78
Screening and treatment of hypercholesterolemia for prevention of coronary heart disease. Manag Care Interface (2006) 0.77
Balancing burdens and benefits: ethical issues of off-label prescription pharmaceutical use. PM R (2013) 0.77
Physician financial incentives and care for the underserved in the United States. Am J Manag Care (2014) 0.77
Academic medical centers and underserved communities: modern complexities of an enduring relationship. J Natl Med Assoc (2010) 0.77
Disposing of medicines safely. Am J Public Health (2014) 0.76
Impact of family structure on stimulant use among children with attention-deficit/hyperactivity disorder. Health Serv Res (2009) 0.76
Shoring up professionalism. Building on disagreements between residents and attending physicians. Can Fam Physician (2006) 0.75
The nuances of self-disclosure. Arch Intern Med (2008) 0.75
Just because it's low cost doesn't mean it's accessible. J Gen Intern Med (2012) 0.75
Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophrenia. Psychiatr Serv (2013) 0.75
Impact of out-of-pocket spending caps on financial burden of those with group health insurance. J Gen Intern Med (2014) 0.75
Drug postmarketing studies--reply. JAMA (2013) 0.75
Cost containment and patient well-being. J Gen Intern Med (2015) 0.75
Academic centers play a vital role in the study of drug safety and effectiveness. Clin Ther (2013) 0.75
Reply letter: are FDA prescription drug safety plans working? A case study of isotretinoin. Pharmacoepidemiol Drug Saf (2014) 0.75
Effect of Direct-to-Consumer Advertising (DTCA) on Statin Use in the United States. Med Care (2017) 0.75
Association between the commercial characteristics of psychotropic drugs and their off-label use. Med Care (2012) 0.75
Brief report: do patients with poor outcomes regret having had infrainguinal bypass surgery? J Surg Res (2007) 0.75
From the editors' desk: The July effect. J Gen Intern Med (2011) 0.75
A comparison of patient and physician beliefs about infrainguinal bypass operation: what role should surgical optimism play? Surgery (2006) 0.75
Can healers have private lives? Virtual Mentor (2006) 0.75
Adherence to a Novel Oral Anticoagulant Among Patients with Atrial Fibrillation. J Manag Care Spec Pharm (2015) 0.75
Lack of effect of guideline changes on LDL cholesterol reporting and control for diabetes visits in the U.S., 1995-2004. Diabetes Care (2005) 0.75
Cost savings associated with filling a 3-month supply of prescription medicines. Appl Health Econ Health Policy (2009) 0.75